Research Topics
| C P CannonSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarctionC P Cannon
Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 34:1395-402. 1999..We sought to review the emerging data and the clinical rationale for combining glycoprotein (GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AMI)...- Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteersC P Cannon
Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
Circulation 99:751-6. 1999.... - Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarctionC P Cannon
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 283:2941-7. 2000..Rapid time to treatment with thrombolytic therapy is associated with lower mortality in patients with acute myocardial infarction (MI). However, data on time to primary angioplasty and its relationship to mortality are inconclusive... - Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trialC P Cannon
Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 102:149-56. 2000..Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events... - Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10AM J Tanasijevic
Clinical Laboratories, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 134:622-30. 1997..The availability of a reliable, noninvasive serum marker of reperfusion may permit early identification of patients with occlusion after thrombolysis who might benefit from further interventions... - Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon
Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
N Engl J Med 344:1879-87. 2001..There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation... - Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudyE M Antman
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 31:326-30. 1998..We sought to determine whether the rapid bedside assay for troponin T identified patients at risk for a more complicated hospital stay and a higher rate of adverse clinical events... - Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
J Am Coll Cardiol 24:1602-10. 1994..The aim of our study was to determine a superior thrombolytic regimen from three: anistreplase (APSAC), front-loaded recombinant tissue-type plasminogen activator (rt-PA) or combination thrombolytic therapy... - Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhageR P Giugliano
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Am Heart J 141:742-50. 2001..The optimal heparin dose as an adjunct to fibrinolysis and its role in causing intracranial hemorrhage (ICH) is unclear... - Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
J Am Coll Cardiol 25:582-9. 1995..This study attempted to determine which lesion characteristics are associated with reocclusion by 18 to 36 h... - Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 35:358-62. 2000.... - C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 31:1460-5. 1998.... - The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial IschemiaC P Cannon
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 30:133-40. 1997..We sought to determine the prognostic value of the admission electrocardiogram (ECG) in patients with unstable angina and non-Q wave myocardial infarction (MI)... - Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trialC M Gibson
Department of Medicine, The Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 80:21-6. 1997.... 
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue
Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 123:1843-53. 2011..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...- Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudyD A Morrow
Department of Medicine and Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 36:1812-7. 2000.... - Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 InvestigatorsC P Cannon
Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Am J Cardiol 87:636-9, A10. 2001..2% vs 3.2% to 3.6% for WBC count < 10,000; p < 0.000). With its simplicity and widespread availability, WBC count could serve as a simple, inexpensive, new tool for risk stratification in acute coronary syndromes... - The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromesJ A de Lemos
Thrombolysis in Myocardial Infarction Study Group, Boston, USA
N Engl J Med 345:1014-21. 2001.... - Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3D A Morrow
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 286:1356-9. 2001..Developed and validated in multiple clinical trials of fibrinolysis, the risk score has not been validated in a community-based population... - Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10BM J Tanasijevic
Clinical Laboratories, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 34:739-47. 1999.... - Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudyC M Gibson
Harvard Clinical Research Institute, Boston, Massachusetts, USA
Circulation 103:2550-4. 2001..These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI... - Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effectM J Sagarin
Harvard Affiliated Emergency Medicine Residency Program, Harvard Medical School, Boston, Massachusetts, USA
J Emerg Med 16:557-65. 1998..The inclusion of patients in this separate population in a general analysis of median door-to-drug times results in an artificial asymptote effect and may confound quality initiatives... - Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trialD A Morrow
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
JAMA 286:2405-12. 2001.... - Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease TrialStephen D Wiviott
Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Circulation 123:1854-63. 2011..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD... - "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE RegistryN K Sekaran
Harvard Medical School, and Brigham and Women s Hospital, Boston, MA 02115, USA
J Thromb Thrombolysis 12:207-16. 2001.... - Combination therapy in the management of mixed dyslipidaemiaC P Cannon
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
J Intern Med 263:353-65. 2008..Careful monitoring is required when adding additional agents given the increased potential for drug interactions and side effects... - Myocardial infarction: contemporary management strategiesE V Gelfand
Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Intern Med 262:59-77. 2007..Finally, evidence-based approach to secondary prevention is outlined... - The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonistsD C Shields
Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland
Pharmacogenomics J 2:182-90. 2002..004). Thus, genetic polymorphisms may be associated with subsequent myocardial infarction, and may also be associated with treatment-associated bleeding among coronary patients... - Enoxaparin in ST elevation MI - a bright futureC P Cannon
Eur Heart J 23:591-2. 2002 - Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromesF F O'Connor
Department of Clinical Pharmacology, and Surgen Ltd, Royal College of Surgeons in Ireland
Blood 98:3256-60. 2001..In patients presenting with an acute coronary syndrome, the Pl(A) polymorphism of GPIIb/IIIa may explain some of the variance in the response to an oral GPIIb/IIIa antagonist... - New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarctionJ S Hochman
Division of Cardiology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284, USA
Arch Intern Med 161:674-82. 2001.... - Ischemic preconditioning: implications for the geriatric heartR A Kloner
Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
Am J Geriatr Cardiol 10:145-8; quiz 149-51. 2001..This observation may lead to a clinical counterpart to successful preconditioning in the older heart... - Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudyV S Srinivas
Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
Am Heart J 142:29-36. 2001..A low 12-hour myoglobin level (< or = 239 ng/mL in this substudy) identifies such patients at low risk and could potentially assist in early risk stratification and triage after ST-segment elevation myocardial infarction... - The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarctionP F Bray
Department of Medicine, Thrombosis Research Section, Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 88:347-52. 2001..These data suggest that it would be important to perform a larger study to address the potential role of these genotypes in therapeutic decision making...